Publications by authors named "De-yan Luo"
The ongoing coronavirus disease 2019 (COVID-19) pandemic has prioritized the development of small-animal models for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We adapted a clinical isolate of SARS-CoV-2 by serial passaging in the respiratory tract of aged BALB/c mice. The resulting mouse-adapted strain at passage 6 (called MASCp6) showed increased infectivity in mouse lung and led to interstitial pneumonia and inflammatory responses in both young and aged mice after intranasal inoculation.
View Article and Find Full Text PDFEnterovirus and Coxsackievirus are the major viruses that cause hand, foot, and mouth disease (HFMD) outbreaks worldwide. Several studies have shown the potential of viral envelope protein 1 (VP1) on providing protective effects from viral strains of different genotypes. However, whether VP1 has the cross-protection in Enteroviruses or Coxsackievirus has not been studied in-depth.
View Article and Find Full Text PDFArticle Synopsis
- - A new 2009 H1N1 virus spread globally, and a live attenuated monovalent flu vaccine (LAMV) has shown good safety and immune response in tests, though more research is needed.
- - Researchers created a cold-adapted version of the vaccine using genetic engineering, combining genes from a pandemic strain and a traditional flu virus.
- - This new candidate vaccine successfully triggered immune responses in mice, providing strong protection against the 2009 H1N1 virus, suggesting it may be ready for further clinical testing.
Background: H3N2 subtype influenza A viruses have been identified in humans worldwide, raising concerns about their pandemic potential and prompting the development of candidate vaccines to protect humans against this subtype of influenza A virus. The aim of this study was to establish a system for rescuing of a cold-adapted high-yielding H3N2 subtype human influenza virus by reverse genetics.
Methods: In order to generate better and safer vaccine candidate viruses, a cold-adapted high yielding reassortant H3N2 influenza A virus was genetically constructed by reverse genetics and was designated as rgAA-H3N2.